Research Paper Volume 12, Issue 9 pp 8137—8150

Figure 1. The expression status of METTL3 and miR-25-3p in T2DM clinical samples and RPE cells. Real-Time qPCR was employed to determine the levels of METTL3 mRNA in (A) clinical serum samples and (B) RPE cells treated with high-glucose for 0 h, 12 h, 24 h and 36 h, respectively. (C, D) Western Blot was conducted to determine the expression levels of METTL3 in RPE cells treated with high-glucose for 0 h, 24 h and 36 h respectively. (E) RPE cells were treated with high-glucose for 0 h, 24 h and 36 h, respectively, the levels of let-7e, miR-221, miR-222, miR-4485, miR-25-3p, miR-93, miR-126 and miR-335 were screened by Real-Time qPCR. (F) The levels of miR-25-3p were measured by Real-Time qPCR in clinical samples. (G) The correlations of miR-25-3p and METTL3 mRNA in the clinical specimens collected from T2DM patients were determined by using the Pearson Correlation Analysis. (H, I) The levels of miR-25-3p were determined by Real-Time qPCR. (J, K) Western Blot was performed to detect the expression status of METTL3 in RPE cells. Each experiment had at least 3 repetitions, the data were collected and represented as Mean ± SD. “*” means p < 0.05 and “**” means p < 0.01.